{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:18:07Z","timestamp":1787242687310,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Dis Travel Med Vaccines"],"DOI":"10.1186\/s40794-025-00256-1","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T18:02:27Z","timestamp":1751824947000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Malaria recrudescence after artemether-lumefantrine treatment in travellers\u2013 a hospital-based observational study and literature review"],"prefix":"10.1186","volume":"11","author":[{"given":"Jenny L.","family":"Schnyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bache E.","family":"Bache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Hoogakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mabel","family":"Van De Ruit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rens","family":"Zonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine M.","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Stijnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"H\u00e4nscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier M.","family":"Van Hest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Goorhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna K.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Grobusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"256_CR1","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.lanepe.2020.100001","volume":"1","author":"M Grobusch","year":"2021","unstructured":"Grobusch M, Weld L, Goorhuis A, Hamer DH, Schunk M, Jordan S, et al. Travel-related infections presenting in Europe: a 20-year analysis of EuroTravNet surveillance data. Lancet Reg Health Eur. 2021;1:100001.","journal-title":"Lancet Reg Health Eur"},{"key":"256_CR2","volume-title":"ECDC. Annual epidemiological report for 2022","author":"European Centre for Disease Prevention and Control","year":"2024","unstructured":"European Centre for Disease Prevention and Control. Malaria. ECDC. Annual epidemiological report for 2022. Stockholm: ECDC; 2024."},{"key":"256_CR3","volume-title":"WHO guidelines for malaria, 14 March 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. WHO guidelines for malaria, 14 March 2023. Geneva, Switzerland: World Health Organization; 2023."},{"key":"256_CR4","unstructured":"World Health Organization. Strategy to respond to antimalarial drug resistance in Africa. 2022."},{"key":"256_CR5","unstructured":"Stichting Werkgroep Antibioticabeleid (SWAB). Malaria Tropica (P. falciparum) 2020 [cited 2023 31rd of July]. Available from: https:\/\/adult.nl.antibiotica.app\/node\/8957"},{"key":"256_CR6","unstructured":"Novartis Pharmaceuticals UK. Ltd. Summary of Product Characteristic: Riamet 20\u00a0mg\/120\u00a0mg Tablets. London, UK 2021."},{"key":"256_CR7","unstructured":"Novartis Pharmaceuticals Corporation. Summary of Product Characteristic: COARTEM 20\u00a0mg\/120\u00a0mg Tablets. New Jersey, United States of America2024."},{"issue":"3","key":"256_CR8","doi-asserted-by":"publisher","first-page":"e0264339","DOI":"10.1371\/journal.pone.0264339","volume":"17","author":"K Marwa","year":"2022","unstructured":"Marwa K, Kapesa A, Baraka V, Konje E, Kidenya B, Mukonzo J, et al. Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis. PLoS ONE. 2022;17(3):e0264339.","journal-title":"PLoS ONE"},{"issue":"1","key":"256_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-11-212","volume":"11","author":"O Bouchaud","year":"2012","unstructured":"Bouchaud O, M\u00fchlberger N, Parola P, Calleri G, Matteelli A, Peyerl-Hoffmann G, et al. Therapy of uncomplicated falciparum malaria in Europe: MALTHER\u2013a prospective observational multicentre study. Malar J. 2012;11(1):1\u20138.","journal-title":"Malar J"},{"key":"256_CR10","unstructured":"World Health Organization. WHO malaria terminology. Global Malaria Programme,. 2019."},{"issue":"2","key":"256_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/cid\/ciw710","volume":"64","author":"K Sond\u00e9n","year":"2017","unstructured":"Sond\u00e9n K, Wyss K, Jovel I, Vieira da Silva A, Pohanka A, Asghar M, et al. High rate of treatment failures in nonimmune travelers treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Sweden: retrospective comparative analysis of effectiveness and case series. Clin Infect Dis. 2017;64(2):199\u2013206.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"256_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4269\/ajtmh.2008.78.241","volume":"78","author":"C Hatz","year":"2008","unstructured":"Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in non-immune populations: a safety, efficacy, and Pharmacokinetic study. Am J Trop Med Hyg. 2008;78(2):241\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"256_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-020-03520-1","volume":"19","author":"R Mumtaz","year":"2020","unstructured":"Mumtaz R, Okell LC, Challenger JD. Asymptomatic recrudescence after artemether\u2013lumefantrine treatment for uncomplicated falciparum malaria: a systematic review and meta-analysis. Malar J. 2020;19:1\u20139.","journal-title":"Malar J"},{"key":"256_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12916-015-0456-7","volume":"13","author":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group","year":"2015","unstructured":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group. Artemether-lumefantrine treatment of uncomplicated plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;13:227.","journal-title":"BMC Med"},{"issue":"2","key":"256_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","volume":"37","author":"NJ White","year":"1999","unstructured":"White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999;37(2):105\u201325.","journal-title":"Clin Pharmacokinet"},{"key":"256_CR16","doi-asserted-by":"publisher","first-page":"e00607","DOI":"10.1016\/j.idcr.2019.e00607","volume":"18","author":"O Koru","year":"2019","unstructured":"Koru O, Yazici E, Rasmussen C, Ringwald P, Artuk C, Bedir O. False resistance after artemether-lumefantrine treatment in a falciparum malaria patient in Turkey: A case report. IDCases. 2019;18:e00607.","journal-title":"IDCases"},{"key":"256_CR17","doi-asserted-by":"crossref","unstructured":"Grossman T, Vainer J, Paran Y, Studensky L, Manor U, Dzikowski R et al. Emergence of artemisinin-based combination treatment failure in patients returning from sub-Saharan Africa with P. falciparum malaria. J Travel Med. 2023:taad114.","DOI":"10.1093\/jtm\/taad114"},{"key":"256_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijid.2021.07.008","volume":"110","author":"A Silva-Pinto","year":"2021","unstructured":"Silva-Pinto A, Domingos J, Cardoso M, Reis A, Benavente ED, Caldas JP, et al. Artemether-lumefantrine treatment failure of uncomplicated plasmodium falciparum malaria in travellers coming from Angola and Mozambique. Int J Infect Dis. 2021;110:151\u20134.","journal-title":"Int J Infect Dis"},{"issue":"Suppl 1","key":"256_CR19","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","volume":"13","author":"S Cuschieri","year":"2019","unstructured":"Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31\u20134.","journal-title":"Saudi J Anaesth"},{"issue":"1","key":"256_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/tp.tp_38_23","volume":"14","author":"K Chawla","year":"2024","unstructured":"Chawla K, Khanna V, Ayer VS, Khanna R. Comparative evaluation of traditional and molecular diagnostic methods for malaria: an analysis of performance. Trop Parasitol. 2024;14(1):30\u20135.","journal-title":"Trop Parasitol"},{"issue":"5","key":"256_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"key":"256_CR22","unstructured":"Nederlandse Vereniging voor Parasitologie. Therapierichtlijn Parasitaire infecties 2020 2020 [cited 2025 February 11th]. Available from: https:\/\/amsterdamumc.adult.nl.antibiotica.app\/sites\/default\/files\/2020-08\/NVP therapierichtlijn 2020_11.pdf"},{"issue":"1","key":"256_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1128\/CMR.00025-08","volume":"22","author":"DL Doolan","year":"2009","unstructured":"Doolan DL, Doba\u00f1o C, Baird JK. Acquired immunity to malaria. Clin Microbiol Rev. 2009;22(1):13\u201336. Table of Contents.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"256_CR24","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/1471-2334-13-428","volume":"13","author":"LT Keegan","year":"2013","unstructured":"Keegan LT, Dushoff J. Population-level effects of clinical immunity to malaria. BMC Infect Dis. 2013;13(1):428.","journal-title":"BMC Infect Dis"},{"key":"256_CR25","volume-title":"IBM SPSS statistics for windows, version 28.0. Armonk","author":"IBM Corp","year":"2021","unstructured":"IBM Corp. IBM SPSS statistics for windows, version 28.0. Armonk. NY, USA: IBM Corp; 2021."},{"issue":"1","key":"256_CR26","doi-asserted-by":"publisher","first-page":"taz082","DOI":"10.1093\/jtm\/taz082","volume":"27","author":"DL Bourque","year":"2020","unstructured":"Bourque DL, Chen LH. Plasmodium falciparum malaria recrudescence after treatment with artemether\u2013lumefantrine. J Travel Med. 2020;27(1):taz082.","journal-title":"J Travel Med"},{"key":"256_CR27","doi-asserted-by":"publisher","first-page":"964","DOI":"10.4269\/ajtmh.20-1310","volume":"104","author":"D Fernando","year":"2020","unstructured":"Fernando D, Weerasekera CJ, Gunasekera W, Hapuarachchi HC, Koo C, Munas M, et al. Case report: the first case of genotypically confirmed plasmodium falciparum Kelch 13 propeller mutation in Sri Lanka and its implications on the elimination status of malaria. Am J Trop Med Hyg. 2020;104:964\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"256_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/1475-2875-11-176","volume":"11","author":"A F\u00e4rnert","year":"2012","unstructured":"F\u00e4rnert A, Ursing J, Tolfvenstam T, Rono J, Karlsson L, Sparrelid E, et al. Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with plasmodium falciparum malaria after returning from Tanzania. Malar J. 2012;11:176.","journal-title":"Malar J"},{"issue":"3","key":"256_CR29","doi-asserted-by":"publisher","first-page":"taad036","DOI":"10.1093\/jtm\/taad036","volume":"30","author":"S Halani","year":"2023","unstructured":"Halani S, Bogoch II. Weight-related malaria treatment failure with artemether-lumefantrine. J Travel Med. 2023;30(3):taad036.","journal-title":"J Travel Med"},{"key":"256_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.7883\/yoken.JJID.2009.139","volume":"62","author":"Y Mizuno","year":"2009","unstructured":"Mizuno Y, Kato Y, Kudo K, Kano S. First case of treatment failure of artemether-lumefantrine in a Japanese traveler with imported falciparum malaria. Jpn J Infect Dis. 2009;62:139\u201341.","journal-title":"Jpn J Infect Dis"},{"key":"256_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5152\/tpd.2014.3169","volume":"38","author":"A \u00dcl\u00e7ay","year":"2014","unstructured":"\u00dcl\u00e7ay A, Karaahmeto\u011flu G, Turhan V, Erdem H, Acar A, \u00d6nc\u00fcl O, et al. [The management of therapeutic failure in a falciparum malaria patient under oral arthemether-lumefantrine therapy]. Turkiye Parazitol Derg. 2014;38:61\u20137.","journal-title":"Turkiye Parazitol Derg"},{"key":"256_CR32","doi-asserted-by":"crossref","unstructured":"Pierreux J, Bottieau E, Florence E, Maniewski U, Bruggemans A, Malotaux J et al. Failure of artemether-lumefantrine therapy in travellers returning to Belgium with plasmodium falciparum malaria: an observational case series with genomic analysis. J Travel Med. 2023;31(3).","DOI":"10.1093\/jtm\/taad165"},{"key":"256_CR33","doi-asserted-by":"crossref","unstructured":"Sutherland CJ, Lansdell P, Sanders M, Muwanguzi J, van Schalkwyk DA, Kaur H et al. pfk13-Independent treatment failure in four imported cases of plasmodium falciparum malaria treated with Artemether-Lumefantrine in the united Kingdom. Antimicrob Agents Chemother. 2017;61(3).","DOI":"10.1128\/AAC.02382-16"},{"issue":"4","key":"256_CR34","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/0049475513499560","volume":"43","author":"F Arslan","year":"2013","unstructured":"Arslan F, Mert A, Batirel A, Inan A, Balkan II, Nazlican O, et al. Imported plasmodium falciparum malaria in Istanbul, Turkey: risk factors for severe course and mortality. Trop Doct. 2013;43(4):129\u201333.","journal-title":"Trop Doct"},{"key":"256_CR35","doi-asserted-by":"publisher","first-page":"102549","DOI":"10.1016\/j.tmaid.2023.102549","volume":"52","author":"V Grebenyuk","year":"2023","unstructured":"Grebenyuk V, Stejskal F, Noh\u00fdnkov\u00e1 E, Zicklerov\u00e1 I, Richterov\u00e1 L, Roh\u00e1\u010dov\u00e1 H, et al. Artemether-lumefantrine, mefloquine and atovaquone-proguanil in the treatment of uncomplicated plasmodium falciparum malaria in travellers: A retrospective comparative study of efficacy and treatment failures. Travel Med Infect Dis. 2023;52:102549.","journal-title":"Travel Med Infect Dis"},{"issue":"6","key":"256_CR36","doi-asserted-by":"publisher","first-page":"833","DOI":"10.11150\/kansenshogakuzasshi.88.833","volume":"88","author":"S Kutsuna","year":"2014","unstructured":"Kutsuna S, Kobayashi T, Kato Y, Fujiya Y, Mawatari M, Ujiie M, et al. [Malaria cases treated with Artemether\/lumefantrine in Japanese travelers]. Kansenshogaku Zasshi. 2014;88(6):833\u20139.","journal-title":"Kansenshogaku Zasshi"},{"key":"256_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.tmaid.2018.02.003","volume":"22","author":"F Nakamura-Uchiyama","year":"2018","unstructured":"Nakamura-Uchiyama F, Katanami Y, Kikuchi T, Takaya S, Kutsuna S, Kobayashi T, et al. Retrospective observational study of the use of artemether-lumefantrine in the treatment of malaria in Japan. Travel Med Infect Dis. 2018;22:40\u20135.","journal-title":"Travel Med Infect Dis"},{"issue":"4","key":"256_CR38","doi-asserted-by":"publisher","first-page":"828","DOI":"10.4269\/ajtmh.18-0722","volume":"100","author":"S Takaya","year":"2019","unstructured":"Takaya S, Kato Y, Katanami Y, Yamamoto K, Kutsuna S, Takeshita N, et al. Imported malaria at a referral hospital in Tokyo from 2005 to 2016: clinical experience and challenges in a Non-Endemic setting. Am J Trop Med Hyg. 2019;100(4):828\u201334.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"256_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12936-024-04858-6","volume":"23","author":"KT Gunasekera","year":"2024","unstructured":"Gunasekera KT, Premaratne RG, Handunnetti SM, Weerasena J, Premawansa S, Fernando DS. msp1, msp2, and Glurp genotyping to differentiate plasmodium falciparum recrudescence from reinfections during prevention of reestablishment phase, Sri Lanka, 2014\u20132019. Malar J. 2024;23(1):35.","journal-title":"Malar J"},{"key":"256_CR40","doi-asserted-by":"publisher","first-page":"101505","DOI":"10.1016\/j.tmaid.2019.101505","volume":"32","author":"E Rovira-Vallbona","year":"2019","unstructured":"Rovira-Vallbona E, Bottieau E, Guetens P, Verschueren J, Rebolledo J, Nulens E, et al. Imported malaria and artemisinin-based combination therapy failure in travellers returning to Belgium: A retrospective study. Travel Med Infect Dis. 2019;32:101505.","journal-title":"Travel Med Infect Dis"},{"key":"256_CR41","volume-title":"Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019)","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019). Geneva, Switzerland: World Health Organization; 2020."},{"issue":"2","key":"256_CR42","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","volume":"11","author":"M Jamei","year":"2009","unstructured":"Jamei M, Turner D, Yang J, Neuhoff S, Polak S, Rostami-Hodjegan A, et al. Population-Based mechanistic prediction of oral drug absorption. AAPS J. 2009;11(2):225\u201337.","journal-title":"AAPS J"},{"issue":"8","key":"256_CR43","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1128\/AAC.02595-14","volume":"58","author":"D Mosha","year":"2014","unstructured":"Mosha D, Guidi M, Mwingira F, Abdulla S, Mercier T, Decosterd LA, et al. Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated plasmodium falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2014;58(8):4583\u201392.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"256_CR44","doi-asserted-by":"publisher","first-page":"106482","DOI":"10.1016\/j.ijantimicag.2021.106482","volume":"59","author":"SR Sugiarto","year":"2022","unstructured":"Sugiarto SR, Page-Sharp M, Drinkwater JJ, Davis WA, Salman S, Davis TME. Pharmacokinetic properties of the antimalarial combination therapy artemether\u2013lumefantrine in normal-weight, overweight and obese healthy male adults. Int J Antimicrob Agents. 2022;59(1):106482.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"256_CR45","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1093\/jac\/dks207","volume":"67","author":"P Byakika-Kibwika","year":"2012","unstructured":"Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H, et al. Significant Pharmacokinetic interactions between Artemether\/lumefantrine and Efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67(9):2213\u201321.","journal-title":"J Antimicrob Chemother"},{"key":"256_CR46","unstructured":"Schnyder JL, Vos-van der Meer M, Van Hest RM, Mathot RAA, Schlagenhauf P, De Jong HK et al. Can hair concentrations of artemether-lumefantrine be used as a tool to retrospectively determine drug exposure during malaria treatment? Submitted for publication. 2025."}],"container-title":["Tropical Diseases, Travel Medicine and Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-025-00256-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40794-025-00256-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40794-025-00256-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T18:02:35Z","timestamp":1751824955000},"score":1,"resource":{"primary":{"URL":"https:\/\/tdtmvjournal.biomedcentral.com\/articles\/10.1186\/s40794-025-00256-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1186\/s40794-025-00256-1","relation":{},"ISSN":["2055-0936"],"issn-type":[{"value":"2055-0936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The medical ethical committee of the Amsterdam UMC approved the study and declared that the study does not fall within the scope of the Dutch Medical Research Involving Human Subjects Act (reference number 2024.0195). Eligible patients were informed by e-mail or letter (depending on the contact details available) about the study with a possibility to opt-out. Records of patients who opted out were excluded from the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}